290 related articles for article (PubMed ID: 35634306)
21. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
Front Immunol; 2021; 12():793964. PubMed ID: 34987518
[TBL] [Abstract][Full Text] [Related]
22. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response.
Sweeney KJ; Tetzlaff MT; Vega F; Gillenwater A; Zuo Z; Gross N; Nagarajan P; Wargo J; Nelson K; Prieto VG; Torres-Cabala CA; Curry JL
J Cutan Pathol; 2021 May; 48(5):674-679. PubMed ID: 33399228
[TBL] [Abstract][Full Text] [Related]
23. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
24. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness.
Khononov I; Jacob E; Fremder E; Dahan N; Harel M; Raviv Z; Krastev B; Shaked Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707313
[TBL] [Abstract][Full Text] [Related]
25. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor.
Mochizuki S; Soejima K; Shimoda M; Abe H; Sasaki A; Okano HJ; Okano H; Okada Y
J Natl Cancer Inst; 2012 Jun; 104(12):906-22. PubMed ID: 22636800
[TBL] [Abstract][Full Text] [Related]
26. Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer.
Zhang L; Zhang R; Jin D; Zhang T; Shahatiaili A; Zang J; Wang L; Pu Y; Zhuang G; Chen H; Fan J
Br J Cancer; 2024 Apr; 130(7):1221-1231. PubMed ID: 38332180
[TBL] [Abstract][Full Text] [Related]
27. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.
Lim JU; Yoon HK
Cytokine; 2021 Feb; 138():155363. PubMed ID: 33264749
[TBL] [Abstract][Full Text] [Related]
28. Tertiary lymphoid structures in the era of cancer immunotherapy.
Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
[TBL] [Abstract][Full Text] [Related]
29. Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer.
Liu R; Huang X; Yang S; Du W; Chen X; Li H
Front Immunol; 2024; 15():1364506. PubMed ID: 38571938
[TBL] [Abstract][Full Text] [Related]
30. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.
Rodriguez AB; Peske JD; Woods AN; Leick KM; Mauldin IS; Meneveau MO; Young SJ; Lindsay RS; Melssen MM; Cyranowski S; Parriott G; Conaway MR; Fu YX; Slingluff CL; Engelhard VH
Cell Rep; 2021 Jul; 36(3):109422. PubMed ID: 34289373
[TBL] [Abstract][Full Text] [Related]
31. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.
Meylan M; Petitprez F; Becht E; Bougoüin A; Pupier G; Calvez A; Giglioli I; Verkarre V; Lacroix G; Verneau J; Sun CM; Laurent-Puig P; Vano YA; Elaïdi R; Méjean A; Sanchez-Salas R; Barret E; Cathelineau X; Oudard S; Reynaud CA; de Reyniès A; Sautès-Fridman C; Fridman WH
Immunity; 2022 Mar; 55(3):527-541.e5. PubMed ID: 35231421
[TBL] [Abstract][Full Text] [Related]
32. A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis.
Sjöberg E; Frödin M; Lövrot J; Mezheyeuski A; Johansson M; Harmenberg U; Egevad L; Sandström P; Östman A
Br J Cancer; 2018 Oct; 119(7):840-846. PubMed ID: 30293996
[TBL] [Abstract][Full Text] [Related]
33. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
Masuda T; Tanaka N; Takamatsu K; Hakozaki K; Takahashi R; Anno T; Kufukihara R; Shojo K; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314433
[TBL] [Abstract][Full Text] [Related]
34. The molecular subtypes and clinical prognosis characteristic of tertiary lymphoid structures-related gene of cutaneous melanoma.
Li J; Chen G; Luo Y; Xu J; He J
Sci Rep; 2023 Dec; 13(1):23097. PubMed ID: 38155221
[TBL] [Abstract][Full Text] [Related]
35. Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
Petroni G; Pillozzi S; Antonuzzo L
Cancer Res; 2024 Apr; 84(8):1199-1209. PubMed ID: 38381540
[TBL] [Abstract][Full Text] [Related]
36. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer.
Sun J; Zhang Z; Bao S; Yan C; Hou P; Wu N; Su J; Xu L; Zhou M
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041817
[TBL] [Abstract][Full Text] [Related]
37. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
38. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
39. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis.
Singh S; Long JP; Tchakarov A; Dong Y; Yee C; Lin JS
JCI Insight; 2022 Dec; ():. PubMed ID: 36472921
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
